Screener
Madrigal Pharmaceuticals, Inc. MDGL Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total operating expenses | 420,560 | 260,004 | 824,620 | 476,565 |
| Loss from operations | (56,308) | (47,202) | (149,031) | (126,513) |
| Interest income | 7,104 | 8,227 | 15,347 | 17,597 |
| Interest expense | (7,940) | (3,264) | (15,759) | (6,561) |
| Other expense, net | (795) | (42) | (2,887) | (42) |
| Net loss | $(57,939) | $(42,281) | $(152,330) | $(115,519) |
| Net loss per common, Series A preferred and Series B preferred share: | ||||
| Basic and diluted net loss per common, Series A preferred, and Series B preferred share | $(1.99) | $(1.50) | $(5.24) | $(4.10) |
Item 1. Financial Statements (Unaudited):
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s interest expense?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported interest expense of $7.94M in Q2 2026.
- How has Madrigal Pharmaceuticals, Inc.'s interest expense changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s interest expense increased by 143.3% year-over-year, from $3.26M to $7.94M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude